| Jul 4 |
CureVac announces restructuring to focus on mRNA projects
|
| Jul 3 |
GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines
|
| Jul 3 |
GSK Will Pay Up to $1.5 Billion for CureVac’s mRNA Vaccines
|
| Jul 3 |
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
|
| Jul 3 |
Biggest stock movers today: Electric vehicle stocks, PARAA, CVAC, and more
|
| Jul 3 |
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
|
| Jul 3 |
GSK to Buy COVID-19, Flu Vaccine Rights From CureVac for $1.56 Billion
|
| Jul 3 |
CureVac cuts jobs, licenses out vaccines to GSK
|
| Jul 3 |
GSK to Buy CureVac’s Covid-19, Flu Vaccine Rights for Up to $1.56 Billion
|
| Jul 3 |
GSK and CureVac restructure mRNA vaccine development deal
|
